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SUMMARY
Progression of non-small-cell lung cancer (NSCLC) to metastasis is poorly understood. Two genetic
approaches were used to evaluate the role of adherens junctions in a C-RAF driven mouse model for
NSCLC: conditional ablation of the cdh1 gene and expression of dominant-negative (dn) E-cadherin.
Disruption of E-cadherin caused massive formation of intratumoral vessels that was reversible in the
early phase of induction. Vascularized tumors grew more rapidly, developed invasive fronts, and
gave rise to micrometastasis. b-catenin was identified as a critical effector of E-cadherin disruption
leading to upregulation of VEGF-A and VEGF-C. In vivo, lung tumor cells with disrupted E-cadherin
expressed b-catenin target genes normally found in other endodermal lineages suggesting that re-
programming may be involved in metastatic progression.INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the most frequent
type of lung cancer with high metastatic potential and
low cure rate (American Cancer Society, 2006). This high
metastatic potential may be due to active angiogenesis
(Folkman et al., 1989). Vascularized NSCLC is well known
for its ability to metastasize into regional lymph nodes
even at early tumor stages, and tumor lymphangiogenesis
is directly correlated with lymph node metastasis (Renyi-
Vamos et al., 2005). Therefore, prevention of early NSCLC
tumor metastasis is a primary therapeutic goal.
Escape of cells from the primary tumor is considered as
a rate-limiting step and requires block of adhesion mole-
cules (Bremnes et al., 2002). Among various adhesion
molecules, cadherin family members were consistentlyshown to be involved in the progression of NSCLC
(Nakashima et al., 2003; Kim et al., 2005). Cadherins are
transmembrane proteins and components of adherence
junctions (Takeichi, 1995). Their extracellular domains
form calcium-dependent, homophilic transdimers that
mediate cell-cell adhesions. The cytoplasmic tails of cad-
herins bind to several potential signaling proteins, most
notably b-catenin, a transcriptional cofactor in Wnt signal-
ing (Clevers, 2006). Overexpression of positive—and
suppression of negative—regulators of Wnt signaling
has been reported for NSCLC (Uematsu et al., 2003;
You et al., 2004; Mazieres et al., 2004). Epithelial (E)-
cadherin is the major mediator of intercellular adhesion
in epithelial tissues. Aberrant expression of E-cadherin
was shown to be highly correlated with invasion and
spread of NSCLC (Shibanuma et al., 1998). Moreover,SIGNIFICANCE
Prevention of metastasis of NSCLC, the most frequent type of human cancer is a primary therapeutic goal. A rate
limiting step in metastasis is disruption of cell-cell contacts. We describe an approach to reversibly disrupt cell-cell
adhesion in C-RAF driven lung adenomas and promote conversion to micrometastasis by induction of cdh1 gene
ablation or expression of dn E-cadherin. Micrometastasis was preceded by massive formation of blood and lymph
vessels. E-cadherin dysfunction is a frequent event in human cancer giving these findings a broader significance.
Insight into the mechanisms of angiogenic switch induction may help in developing novel strategies for prevention
of malignant progression.Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 145
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Induction of Angiogenic Switch in Lung Cancerreduced or absent expression of E-cadherin was reported
to be a significant prognostic factor in patients with
NSCLC (Liu et al., 2001; Huang et al., 2005). However,
how disruption of E-cadherin complexes may cause lung
tumor progression remains largely unresolved.
In order to elucidate the role of E-cadherin in NSCLC,
we took advantage of a transgenic mouse model of
NSCLC, SP-C C-RAF BXB, that expresses oncogenic C-
RAF in type II alveolar pneumocytes (Kerkhoff et al.,
2000). SP-C C-RAF BXB mice reproducibly develop mul-
tiple lung adenomas early in postnatal life. Adenomas con-
sist of cuboidal cells that grow continuously without signs
of apoptosis (Fedorov et al., 2002; Go¨tz et al., 2004) and
eventually kill the host by elimination of gas exchange sur-
face. Progression of the SP-C C-RAF BXB adenomas to
metastasis was neither observed in aged animals (Ker-
khoff et al., 2000) nor after removal of p53 (Fedorov
et al., 2003), making this transgenic model an ideal system
for identification of NSCLC progression factors (Rapp
et al., 2003). We hypothesized that oncogenic C-RAF
might stabilize cell-cell interaction of the adenoma cells
that might in turn contribute to the benign nature of the tu-
mor cells. We therefore investigated whether disruption of
E-cadherin might cause progression of SP-C C-RAF BXB
adenomas. For disruption, we used two approaches,
doxycycline (DOX)-inducible Cre recombinase-mediated
E-cadherin (cdh1) gene inactivation or expression of dom-
inant-negative (dn) E-cadherin (Dahl et al., 1996).
Transgenic mice conditionally disrupting E-cadherin
function in type II alveolar epithelial cells were crossed
with SP-C C-RAF BXB mice. In normal lung, inhibition of
E-cadherin expression did not lead to overt tumor forma-
tion, but diffuse hyperplasia was observed. Disruption of
E-cadherin complexes in adenoma cells induced invasive
carcinoma that metastasized into regional lymph nodes
and bone marrow. Tumor progression was reversible
and strictly correlated with the induction of angiogenic
switch presumably via b-catenin-mediated VEGF-A and
VEGF-C upregulation. Taken together, these results re-
veal a novel and unanticipated function of E-cadherin as
an important mediator of angiogenesis which might shed
light on the missing link between E-cadherin loss and tu-
mor progression.
RESULTS
Angiogenic Switch Induction in C-RAF BXB Lung
Adenomas by Ablation of E-Cadherin
A hallmark of SP-C C-RAF BXB lung adenomas is tight
cell-cell association maintained over the lifetime of the an-
imal (Fedorov et al., 2003; Houben et al., 2004). To exam-
ine whetherSP-CC-RAFBXB epithelial tumors express E-
cadherin, individual adenomas were microdissected from
frozen lung sections of adult SP-C C-RAF BXB transgenic
mice. We readily detected cdh1 transcripts by RT-PCR
(see Figure S1A in the Supplemental Data available with
this article online). For localization of endogenous E-cad-
herin, lung sections were stained with an antibody to the
extracellular domain of E-cadherin. All cuboidal tumor146 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.cells expressed functional E-cadherin in the membrane
(Figure S1B and S1C).
To examine whether E-cadherin ablation would affect
tumor progression, we first employed conditional cdh1
gene inactivation using a DOX inducible Cre/loxP site-
specific recombination system (Figure S2A). For this, Cre
recombinase was induced in 6-week-old compound mice
(SP-C rtTA/Tet-O-cre/cdh1flox/flox) by DOX treatment, and
lungs were analyzed after a 2 month period. In the pres-
ence of DOX, no tumors were formed, though there was
diffuse hyperplasia accompanied by enlargement of alve-
olar spaces in the absence of inflammation (Figure S4A).
These hyperplastic lesions showed scattered cells of un-
polarized morphology and a marked increase in prolifera-
tion (Figures S4A and S4C). Further, evaluation of these
mice for periods up to 10 months did not reveal overt tu-
mor formation. To evaluate the effect of cdh1 loss on tu-
morigenesis, tumor-bearing mice (SP-C C-RAF BXB/SP-
C rtTA/Tet-O-cre/cdh1flox/flox) of 6 weeks of age were
treated with DOX for 4 months and subsequently exam-
ined histologically. Tumor foci showed cell separation
and partial loss of cuboidal morphology (Figure 1A). Nota-
bly, ablation of E-cadherin did not occur in all cells, consis-
tent with scattered Cre staining in only 35–50 percent of
cells in tumor foci (Figures 1A, 1B and Figure S2B). The
most dramatic finding came from analysis of blood vessel
density by CD31 staining which revealed massive intratu-
moral invasion after cdh1 inactivation, whereas adenomas
harboring intact cdh1 alleles were poorly vascularized
(Figures 1A and 1D). Vessel induction outside of tumors
was difficult to evaluate because of the abundance of ves-
sels in normal lung. To examine whether cdh1 loss had any
effect on intratumoral lymphangiogenesis, we stained tu-
mors with a lymphatic-specific marker, LYVE-1. Whereas
tumors from untreated mice revealed poor lymphatic ves-
sels in the center of adenomas, their number and size have
significantly increased by 4 months of DOX induction (Fig-
ures 1A and 1E). In search of potential mediators of angio-
genesis, we have stained the sections for b-catenin. There
was a significant loss of membrane staining (data not
shown) and an increased nuclear accumulation of b-cate-
nin in a small fraction of tumor cells (Figures 1A–1C).
As further dissection of this process requires a system
for reversible inactivation of E-cadherin, which Cre-medi-
ated ablation does not allow, we turned to the well estab-
lished dn E-cadherin approach (Dahl et al., 1996; Caval-
laro and Christofori, 2004) and generated mice carrying
a DOX-regulated dn E-cadherin transgene (Figure S3A).
Consistently in compound mice (SP-C rtTA/Tet-O dn
E-cadherin), the expression of dn E-cadherin by DOX
treatment for different periods led to hyperplasia, but
again no tumors formed (Figure S4A). The extent of diffuse
hyperplasia and alveolar space enlargement was compa-
rable to cdh1 gene ablation (Figure S4A). These hyper-
plastic lesions showed a marked increase in proliferation
(Figures S4A and S4C). Silencing of dn E-cadherin expres-
sion by withdrawal of DOX for 2 months led to a pro-
nounced regression of the hyperplastic regions, coinci-
dent with a return to physiological cell-cycle status
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Induction of Angiogenic Switch in Lung CancerFigure 1. Conditional Deletion of cdh1 in SP-C C-RAF BXB Lung Adenomas Provokes Vascular Invasion
(A) Representative paraffin embedded sections of lung tumors from compound mice (SP-C C-RAF BXB/SP-C rtTA/Tet-O-cre/cdh1flox/flox) were
stained as indicated. For Cre-mediated deletion of cdh1, mice were treated with DOX for 4 months starting at 6 weeks of age (ON DOX) and compared
with untreated controls (OFF DOX). Membrane loss of E-cadherin leads to cell-cell separation and is paralleled by relocalization of b-catenin to the
cytoplasm and cell nucleus (arrows and inset). This is accompanied by massive invasion of blood and lymph vessels.
(B–E) Quantification of E-cadherin in the membrane of intratumoral cells, of b-catenin relocalization and of intratumoral blood and lymph vessels. Ten
tumor areas (approximately 200 cells per area) for each of five mice were evaluated for E-cadherin and b-catenin. To enumerate vessel density, 10
tumor areas (10,000 mm2) per mouse were counted in eight mice. All values are mean ± SD (***p < 0.001; ns = nonsignificant). Scale bars, 50 mm.(Figures S4A and S4C). To determine whether regression
of the hyperplastic lesions was caused by apoptosis, we
performed active caspase-3 staining. We observed a
significant increase in cells that contained activated
caspase-3 following restoration of E-cadherin membrane
expression. Search for compensatory upregulation of P-
cadherin was negative in all genotypes (Figure S4D).
To assess whether dn E-cadherin-mediated disruption
of cell adhesion leads to malignancy in benign SP-C C-
RAF BXB adenomas, triple transgenic mice (SP-C C-RAFBXB/SP-C rtTA/Tet-O dn E-cadherin) were treated with
DOX for different periods. Already after 1 week of DOX ad-
ministration, loss of cell-cell contact between tumor cells
was observed (Figure 2A). Using an antibody directed
against the ectodomain of E-cadherin that only detects
membrane inserted E-cadherin, we observed almost
complete removal from the membrane 4 months after in-
duction (Figures 2A and 2B). Displacement from the cell
surface was not paralleled by a corresponding decrease
in E-cadherin protein that was detected at only a slightlyCancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 147
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Induction of Angiogenic Switch in Lung CancerFigure 2. Expression of dn E-Cadherin
Induces Tumor Vasculature
(A) Triple transgenic mice (SP-C C-RAF BXB/
SP-C rtTA/Tet-O dn E-cadherin) at 6 weeks
of age were treated with Dox for 1 week and
compared with age-matched controls. Note
pronounced cell separation in the H&E staining
that correlates with the fraction of cells show-
ing transgene expression. After 4 months in-
duction, loss of membrane E-cadherin and re-
localization of b-catenin (see arrows and inset)
is apparent. At higher magnification, H&E
staining suggests emergence of microvessels
in tumors. Staining for blood (CD31) and lymph
(LYVE-1) endothelial cells demonstrates angio-
genic switch. Scale bars, 50 mm.
(B and C) Quantification of E-cadherin expres-
sion in membranes and of b-catenin relocaliza-
tion was as described in Figure 1; ***p < 0.001.
(D) Immunoblot of isolated tumor cells from tri-
ple transgenic mice treated as indicated were
reacted with antibodies against E-cadherin,
b-catenin, myc-epitope, (dn E-cadherin) or
GAPDH as loading control. M = month.decreased level (Figures 2A and 2D). Removal of E-cad-
herin from the plasma membrane was, however, accom-
panied by nuclear relocalization of b-catenin in tumor cells
expressing dn E-cadherin (Figures 2A and 2C). Nuclear b-
catenin-positive cells were only a fraction (approximately
8%) of E-cadherin downregulated cells demonstrating
heterogeneity in the induced tumor cell population. Con-
sistent with the observations made in the course of cdh1
gene inactivation, 2 months of dn E-cadherin expression
led to uniform penetration of tumors by vessels of in-
creased size that was even more pronounced after 4
months (Figure 2A) and continued to increase in density
by 8 months of induction (Figure 3D and data not shown).
Staining of lung sections for CD31 confirmed strong
induction of intratumoral vessels (Figure 2A and
Figure 3D). There was a 3-fold increase in vessel number
and a 4-fold increase in vessel size (Figure 3D) indicating148 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.an enormous level of neoangiogenesis. As lymphangio-
genesis may be most relevant for metastasis, we exam-
ined presence of vessels positive for the lymphangiogen-
esis marker LYVE-1. We observed that tumors from
untreated mice revealed poor lymphatic vessels in the
center of adenomas (Figures 2A and 3D). After four
months of dn E-cadherin induction, their number and
size had increased significantly (Figure 2A and
Figure 3D) and increased even further when treatment
was continued for 8 months (Figure 3D). To confirm the
lymphatic nature of the vessels, Prox1 staining was addi-
tionally used (Figure S5A). Similar data were obtained with
tissues from induced triple transgenic or cdh1-ablated
quadruple transgenic mice (Figure S5A and S5B). We con-
clude that E-cadherin ablation induces the angiogenic
switch that has previously been reported as a requirement
for tumor progression (Folkman et al., 1989).
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Induction of Angiogenic Switch in Lung CancerFigure 3. Reversal of the Angiogenic Switch via Endothelial Cell Apoptosis after Restoration of E-Cadherin Expression
(A) Reexpression of membrane E-cadherin in tumor cells of triple transgenic mice (SP-C C-RAF BXB/SP-C rtTA/Tet-O dn E-cadherin) that were kept
on DOX for 2 months followed by 2 months DOX withdrawal.
(B and C) Restoration of E-cadherin expression is correlated with disappearance of blood (CD31) and lymph (LYVE-1) vessels.
(D) Quantification of blood and lymph vessels in number and size mm. Ten tumor areas (10,000 mm2) per mouse were counted in 10 mice except in the
ON/OFF category for which 5 mice were evaluated. M = month. All values are mean ± SD (*p < 0.05; ***p < 0.001).
(E) Detection of apoptosis of CD31 positive endothelial cells (see arrows) in frozen tumor sections after DOX withdrawal. Controls include TUNEL
assay without terminal transferase (top panel left), antibody specificity (CD31, top panel middle) and apoptosis induction by DNaseI (second panel).
Note that tumor vasculature in 4-months-induced mice is no longer DOX dependent. For each treatment, three mice and at least 5 tumors per mouse
were evaluated. Scale bars, 50 mm.Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 149
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Induction of Angiogenic Switch in Lung CancerRestoration of Intratumoral E-cadherin Expression
Reverses the Angiogenic Switch
To determine whether restoration of E-cadherin mem-
brane expression leads to suppression of vessel growth,
dn E-cadherin transgene expression was switched off by
DOX withdrawal for 2 months. E-cadherin expression at
the cell surface of tumor cells was restored demonstrating
reversibility (Figure 3A). CD31 staining after 2 months of
DOX removal revealed blood vessel regression in both
number and size (Figures 3B and 3D). To examine whether
vessel regression was caused by endothelial cell apopto-
sis, we performed CD31/TUNEL double staining. Sections
treated without primary antibody or enzyme were used as
negative control (Figure 3E, upper panel). DNase-I treat-
ment served as a positive control (Figure 3E, second
panel). Endothelial intratumoral apoptosis occurred in 2
month ON DOX/1 week OFF DOX mice (Figure 3E, third
panel). Additionally there may have been tumor cell apo-
ptosis as we also see CD31 negative apoptotic cells in
the same tumor section. Interestingly, using a 4 month
ON DOX/1 week OFF DOX schedule, almost no TUNEL
positive endothelial cells were detected (Figure 3E, bot-
tom panel), indicating that long-term loss-of-membrane
E-cadherin expression led to neovascularization that
was resistant to re-expression of E-cadherin. Similar ob-
servations were made regarding vessel size (data not
shown). As in the case of neoangiogenesis, we tested re-
versibility of lymphangiogenesis using a 2 month ON DOX/
2 month OFF DOX schedule. The pattern of reversibility of
lymphangiogenesis was similar to blood angiogenesis as
complete reversibility was seen only after 2 months treat-
ment (Figures 3C and 3D and data not shown).
Tumor Progression in SP-C C-RAF BXB Lung
Tumors after E-cadherin Disruption
To investigate long-term effects of cdh1 deletion or dn E-
cadherin expression, compound mice were kept under
continuous DOX treatment for up to 13 months. After 4
months, we observed large invasive tumors that were dif-
fusely scattered throughout the lung parenchyma
(Figure 4A) as well as loss of cuboidal cell morphology
within tumors (Figure 2A, high magnification H&E pic-
tures). Tumor volume was increased 5-fold (Figure 4B).
Prolongation of induction to 8 months generated macro-
scopic solid tumors that were diagnosed as adenocarci-
nomas (Figure 4A). Cooperation between dn E-cadherin
and C-RAF BXB in accelerating tumor growth required
continued induction, as a 4 month ON DOX/4 month
OFF DOX schedule reduced tumor size to the level of 8
month OFF DOX C-RAF BXB only (Figure 4B). Macro-
scopic tumors retained expression of SP-C and thyroid
transcription factor-1 (TTF-1), a marker of human
adenocarcinomas (data not shown). Tumor progression
frequently involves processes such as epithelial-
mesenchymal transition (EMT) and cadherin switch (loss
of E-cadherin and gain of N-cadherin) (Huber et al.,
2005). For detection of EMT, lung tumor sections were
stained with vimentin and N-cadherin antibodies. There
were scattered vimentin or N-cadherin positive cells in150 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.the induced tumors that most likely represent vessel asso-
ciated cells as no double-positive (pro SP-C/Vimentin; pro
SP-C/N-cadherin) cells were detected (Figures S6A and
6B). To confirm that the increased N-cadherin staining re-
sulted from endothelial rather than tumor cells, we have
isolated tumor and endothelial cell fractions by panning
from triple transgenic mice and performed western blot-
ting. There was no N-cadherin protein detectable in tumor
cells from untreated or treated mice (Figure S6C), whereas
the endothelial fraction showed positive staining indepen-
dent of DOX treatment (Figure S6D). These data sug-
gested that there was no cadherin switch in our lung tu-
mors that has been frequently observed in EMT
(Birchmeier, 2005). Finally, tumor cells from induced
mice had stable epithelial features as cytokeratin staining
was retained (Figure S6A). We conclude that, as in case of
cdh1 gene deletion in quadruple compound mice
(Figure 4A and data not shown), dn E-cadherin-induced
tumor progression of SP-C C-RAF BXB driven lung ade-
nomas may not involve classical EMT. To examine how
disruption of cell-cell contacts induced tumor progres-
sion, we determined the proliferation rate of tumor cells.
PCNA staining of tumor cells in SP-C C-RAF BXB/SP-C
rtTA/Tet-O dn E-cadherin mice and Ki67 staining in
SP-C C-RAF BXB/SP-C rtTA/Tet-O-cre/cdh1flox/flox mice
were highly increased, compared to animals in the
absence of DOX (Figures 4C–4E). Taken together, these
results demonstrate that inactivation of E-cadherin in
benign SP-C C-RAF BXB adenomas not only promotes
tumor growth, but also leads to progression to
adenocarcinomas.
E-Cadherin Disruption Promotes Progression
of SP-C C-RAF BXB Adenomas to Micrometastasis
To examine whether inhibition of E-cadherin function in
benign SP-C C-RAF BXB-driven lung adenomas is neces-
sary and sufficient for the metastatic spread of tumor cells,
we conducted a large scale search for ectopic cells ex-
pressing SP-C or cytokeratin before and after induction.
We detected both cytokeratin (Figure 5A, upper panel)-
and SP-C (Figure 5A, lower panel)-positive cells in the
lymph nodes after cdh1 deletion or dn E-cadherin expres-
sion. The metastatic cells were not growing into tumors
but formed small clusters of one to five cells identifying
them as micrometastasis (Schardt et al., 2005) in medias-
tinal and axillary lymph nodes. Neither SP-C nor cytoker-
atin positive cells were visible in lymph nodes from
untreated age-matched control mice (Figure 5A). Although
we were not able to detect any distant metastasis in the
preferred target tissues of NSCLC such as liver and brain,
we infrequently observed SP-C positive cells in the bone
marrow of triple transgenic mice induced for dn E-cad-
herin (Figure 5A, lower panel on the right). Dissemination
of tumor cells from primary tumors was a late event, as
we never detected metastasis in transgenic mice younger
than 9 months (Figure 5B). Moreover, even in older mice,
despite long-term inactivation of E-cadherin, only 43%
of all triple transgenic mice and 25% of quadruple com-
pound mice developed lymph node micrometastasis.
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Induction of Angiogenic Switch in Lung CancerFigure 4. Oncogenic C-RAF and E-Cadherin Ablation Cooperate in Acceleration of Tumor Growth and Progression to Invasive
Adenocarcinoma
(A) Macroscopic tumors are visible after 8 months DOX induction. Accelerated tumor growth and formation of invasive fronts (indicated by arrows) are
already apparent after 4 months induction of either Cre recombinase to delete the cdh1 gene or of dn E-cadherin expression.
(B) Quantification of tumor volume (n = 10 animals; for details see supplemental experimental procedures). Note that the difference in tumor volume
between 4M ON DOX and 4M ON DOX/4M OFF DOX is not significant (p = 0.126). The difference between 8M OFF DOX and 4M ON DOX/4M OFF
DOX is also not significant (p = 0.60).
(C) PCNA (brown) and Ki67 (green) staining show increased proliferation rates after 4 months induction of either Cre recombinase to delete the cdh1
gene or of dn E-cadherin expression.
(D) Quantification of PCNA-positive cells (n = 5 animals).
(E) Quantification of Ki67-positive cells (n = 5 animals).
Values represent mean ± SD (**p < 0.01; ***p < 0.001). Scale bars, 50 mm except for intact lung which is 2 mm.Induction of dn E-cadherin or ablation of cdh1 alone did
not result in metastasis (data not shown). As in the case
of angiogenic switch induction by dn E-cadherin, we
wanted to examine whether continuous induction was re-
quired for progression to metastasis. Toward this end, we
performed histological analysis of tissues from mice that
were kept on 4 months ON DOX/4–9 months OFF DOX
schedules (Figure 5A). This experiment revealed that
none of the transgenic mice displayed lymph node or dis-
tant metastasis after DOX removal (Figure 5B). We con-
clude that there is a direct correlation between continuousangiogenesis induction and micrometastasis of C-RAF
BXB-driven lung tumors.
Role of b-Catenin Signaling in dn E-Cadherin-
Mediated Tumor Progression
To further resolve by which mechanism dn E-cadherin
provokes tumor angiogenesis and micrometastasis during
SP-C C-RAF BXB lung tumor progression, we analyzed
expression of a panel of candidate genes using real time
RT-PCR analysis. To avoid secondary gene expression
changes due to tissue disaggregation, we chose to focusCancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 151
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Induction of Angiogenic Switch in Lung CancerFigure 5. Oncogenic C-RAF and E-cadherin Ablation Cooperate in Progression to Micrometastasis
(A) Paraffin-embedded lymph node sections from untreated mice or mice treated with DOX for 10 months were screened for regional and long-
distance metastasis by staining for pancytokeratin and pro SP-C (brown). Sections shown in higher magnifictions are boxed. Arrows mark positive
cells. pro SP-C positivity (green) in cytospin preparations of bone marrow. Scale bars, 50 mm.
(B) Incidence and latency of lymph node micrometastasis. M = month.on early events taking place during tumor progression.
Adult triple transgenic mice were treated with DOX for
36 hr. Increased luciferase expression was observed
and confirmed that transgene induction had occurred
(data not shown). Short term induction typically led to
hemorrhage at multiple sites, presumably as a result of
vessel leakage (Figure 6A). Because VEGF family mem-
bers were shown to be primary regulators of angiogenesis
in NSCLC (Nakashima et al., 2004), we first evaluated
VEGF mRNA expression levels. Interestingly, in compari-
son to the untreated control mice, we consistently ob-
served a 1.8-fold increase in the level of VEGF-A and
a 1.9-fold increase VEGF-C but not VEGF-D expression
(Figure 6B and Table S2). Additionally, we noted a 3-fold
increase in the level of VEGFR-3 (or Flt-4) (Figure 6B), a
tyrosine kinase receptor for VEGF-C, suggesting that an
autocrine loop may contribute to the higher proliferation
observed in induced tumor cells (Figures 4C-E). Tran-
scripts for the endothelial cell adhesion molecules
VE-cadherin and PECAM-1 were significantly amplified,152 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.indicating a dynamic angiogenesis process in SP-C C-
RAF BXB lung tumors in response to dn E-cadherin ex-
pression (Table S2). These data demonstrate that the on-
set of angiogenesis in triple transgenic lung tumors may
be a direct effect of dn E-cadherin signaling via VEGF-A
and VEGF-C.
Since E-cadherin competes with Apc for the binding of
b-catenin, we examined the potential involvement of Wnt/
b-catenin signaling in the cooperation of oncogenic C-
RAF in conjunction with dn E-cadherin induction. Compar-
ison of b-catenin mRNA levels in SP-C C-RAF BXB lung
tumors revealed increased expression of b-catenin after
36 hr DOX treatment (Figure 6B and Table S2). Among var-
ious b-catenin target genes investigated, cyclin D1 was
significantly elevated (Figure 6B). Thus, b-catenin may
be an important effector of dn-E-cadherin induction.
This possibility was further examined using two lung epi-
thelial cell lines derived from NSCLC-type tumors, the
mouse 3041 line (Rizzino et al., 1982) and the human
A549 cell line. Transfection of Tet-O dn E-cadherin and
Cancer Cell
Induction of Angiogenic Switch in Lung CancerFigure 6. Acute Induction of dn E-Cad-
herin Leads to Elevated Expression of
Target Genes for Angiogenesis
(A) Strategy for detection of transcripts during
angiogenic switch induction. Six-week old tri-
ple transgenic mice were induced (36hr DOX
pulse) or left untreated; note vessel leakage in
the induced lung. Scale Bars, 2 mm.
(B) Quantitative real time RT-PCR from total
lung. Transcripts included candidate angio-
genic switch genes as well as b-catenin target
genes that have been functionally linked to an-
giogenesis and cell cycle control. Values repre-
sent the average of triplicate samples of six
mice for each condition. hr = hour.a SP-C rtTA expressing activator plasmid alone or in con-
junction with SP-C C-RAF BXB showed elevated VEGF
staining 24 hr after transfection (Figures 7A and 7B). By
transfection of a constitutively active b-catenin, b-catenin
4S, a similar level of VEGF induction was achieved (Fig-
ures 7A and 7B). Notably, neither in 3041 nor in A549 cells
did SP-C C-RAF BXB induce VEGF expression (Figures
7A and 7B). After dn E-cadherin transfection, b-catenin
was relocalized from the membrane and presumably made
available to the cytoplasmic signaling pool similar to the
constitutively active b-catenin 4S (Herzig et al., 2007) (Fig-
ures 7A and 7B, Figures S8A and S8B). To unravel the sig-
naling cascade between dn E-cadherin and VEGF induc-
tion, we next investigated the role of b-catenin by
addition of b-catenin siRNA. Notably, b-catenin siRNA
suppressed VEGF expression in both 3041 and A549 tu-
mor cell lines (Figures 7A and 7B). To further evaluate
these observations, we determined the mRNA levels of
VEGF-A and VEGF-C expression by real-time PCR analy-
sis. Expression of dn E-cadherin increased the level of
VEGF-A transcripts in a b-catenin dependent fashion, irre-
spective of C-RAF BXB coexpression in either cell line
(Figures S7A and S7B). Different results were observed
when we analyzed VEGF-C mRNA expression that was
b-catenin independent (Figure S7B), even though b-cate-
nin 4S was a powerful inducer of VEGF–C in both cell lines.
These differences suggest that, for VEGF-C induction by
dn E-cadherin, other pathways exist besides b-catenin-Cmediated signaling. There was also suggestive evidence
for a suppression of VEGF-C by b-catenin in both cell lines
although the effect was significant only in A549 cells
(Figure S7B). In summary, in our transgenic NSCLC
model, b-catenin plays a key role in the induction of cell-
cycle progression of tumor cells and angiogenesis.
Chronic Expression of dn E-Cadherin in SP-C
RAFBXB-Expressing Lung Epithelial Cells
Upregulates b-Catenin-Responsive Genes that
Include Endodermal and Other Lineage Markers
Previous data on SP-C-driven b-catenin signaling in
embryonic lung, using expression of a fusion protein con-
taining the aminoterminus of LEF-1 linked to the transac-
tivation domain of b-catenin, had highlighted increased
expression of genes associated with other endodermal
lineages (Okubo and Hogan, 2004). We therefore ex-
tended our RT-PCR analysis to lung tumors from 4 months
induced mice. Importantly, six of six genes selected from
the list found to be ectopically expressed during embryo-
genesis (Okubo and Hogan, 2004) were upregulated
in alveolar type II cells in adult mice to various extents
(Figure 8). Most prominent was ectopic expression of
the transcriptional regulators Tcf4 and Tcf1 and high
mobility group box transcription factor Cdx1. Moreover,
Wnt-2 was induced, which is normally expressed prefer-
entially in mesenchymal cells and has a role in early devel-
opment of lung and intestine but has also been shown toancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 153
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mas (Mazieres et al., 2004). As in the case of lung-targeted
expression of constitutive b-catenin signaling during em-
bryogenesis, ectopic expression was not confined to
genes of the intestinal endoderm but included for example
DCPP that is normally active in sublingual and salivary
glands. Considering that we have constitutive b-catenin
signaling in the DOX-treated triple transgenic mice, we
also asked whether negative feed-back regulators of the
Wnt pathway (Dkk4, Nkd1, Wif1, and Axin-2) might be up-
Figure 7. b-Catenin Dependence of dn E-Cadherin-Mediated
VEGF Induction
Epithelial mouse lung 3041 and human NSCLC A549 cells were trans-
fected with non specific siRNA (ns siRNA), b-catenin specific siRNA (b-
cat siRNA) and DNA constructs as indicated. A constitutively active
mutant of b-catenin, b-catenin 4S, was included.
(A) 3041 cells. Representative immmunocytochemistry staining iden-
tifies VEGF expression (red) in tumor cells transfected with dn E-cad-
herin in the presence or absence ofC-RAF BXB. Expression of VEGF is
strongly reduced by b-catenin siRNA. b-catenin siRNA also strongly
reduced endogenous b-catenin (green) in transfected tumor cells.
Note the redistribution of b-catenin from membrane to cytosol in cells
expressing dn E-cadherin or b-catenin 4S. Scale Bars, 10 mm.
(B) A549 cells. Details as in (A), except for b-catenin staining (red).154 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.regulated (Deque´ant et al., 2006). Of these,Wif1 and Nkd1
were clearly upregulated whereas Axin-2 showed weekly
increased levels. Taken together, these data support the
notion that b-catenin is a major effector of dn E-cadherin
and raise the possibility that forced simultaneous Wnt/
RAF signaling generates phenotypic heterogeneity in tu-
mors that may contribute to metastatic conversion.
DISCUSSION
Two strategies were followed to disrupt E-cadherin
function in normal and SP-C C-RAF BXB transgenic ade-
nomatous alveolar type II cells, DOX inducible cdh1 gene
ablation and expression of dn E-cadherin. Use of this
transgenic strain with its discrete premalignant lesion al-
lowed us to study NSCLC progression and to evaluate
the role of cell-cell adhesion in progression of NSCLC-
like lung adenomas to metastatic adenocarcinoma. The
striking finding was that interference with E-cadherin func-
tion not only broke cell-cell contacts but contributed to tu-
mor progression by massive induction of angiogenesis.
Attempts to delineate the mechanism of angiogenesis in-
duction highlighted b-catenin as a critical effector of VEGF
induction by abrogation of E-cadherin. Disruption of cell-
cell contacts and induction of angiogenesis was sufficient
to promote micrometastasis.
Is Interference with E-Cadherin Function
Oncogenic?
Both strategies to genetically disrupt E-cadherin mediated
cell-cell contacts, ablation of cdh 1 or dn E-cadherin in-
duction failed to induce tumor formation in normal lung.
Similar observations about lack of tumor formation upon
loss of function of E-cadherin has been reported previ-
ously (Boussadia et al., 2002) by conditional knockout of
cdh1 in alveolar epithelial cells of the mammary gland us-
ing MMTV-Cre mice. More recently, the effects of E-cad-
herin loss on mammary tumorigenesis were studied by
use of K14cre mice leading to E-cadherin loss in ductal
and alveolar epithelium (Derksen et al., 2006). No tumor
formation was observed in the mammary gland or in the
skin which also expresses Cre in epithelium (Jonkers
et al., 2001; Derksen et al., 2006). These data on skin
were similar to an earlier report by Tinkle et al. who, in ad-
dition, observed compensatory upregulation of P-cad-
herin resulting in a hyperproliferative response (Tinkle
et al., 2004). Our data in the lung are comparable to those
of Tinkle et al., as we observe diffuse hyperplasia in mice
with either genetic condition to disable E-cadherin in lung
alveolar type II cells. In contrast to skin, we did not observe
a compensatory P-cadherin upregulation. N-cadherin ex-
pression also remained unchanged. We conclude that
cdh1 knockout or dn E-cadherin induction is not sufficient
for lung tumorigenesis.
Induction of Angiogenic Switch by Disruption
of E-Cadherin
Lung adenomas induced by C-RAF BXB are notoriously
stable, a feature that may result from high E-cadherin
Cancer Cell
Induction of Angiogenic Switch in Lung CancerFigure 8. Expression of b-Catenin Responsive Genes in Chronically Induced Mice Reveals Reprogramming
Type II pneumocytes were prepared from mice of different genotypes as indicated. Triple transgenic mice were induced for 4 months and used for RT-
PCR. The panel of b-catenin responsive target genes includes components of the Wnt pathways (Wnt-2, Tcf-1, Tcf-4, Dkk4, Nkd1, Wif-1, and Axin2),
cell-cycle regulators (cyclin D1, c-myc), and previously identified endodermal selector genes (Atoh-1, Cdx-1), as well as secretory lineage of the tra-
chea (DCPP). SP-C was used to confirm the identity of the type II epithelial cells, and b-actin was used as control for RNA integrity.expression. One way by which cadherin junctions may
contribute to stability of C-RAF BXB adenomas is by sup-
pression of angiogenesis. Evidence for suppression was
obtained by our findings that disruption of cell-cell contact
by cdh1 gene ablation or expression of dn E-cadherin in
C-RAF BXB adenomas was followed by massive angio-
genesis correlating with appearance of nuclear b-catenin
in a fraction of tumor cells and their invasive behavior.
These data demonstrate for the first time that the disrup-
tion of E-cadherin leads to the induction of the angiogenic
switch in a preexistent adenoma and consequent progres-
sion to adenocarcinomas. Consistent data regarding
blood angiogenesis were presented in a recent publica-
tion that examined effects of Cdh1 loss in a model for
invasive lobular breast cancer (Derksen et al., 2006). How-
ever, no data on lymphangiogenesis were included in this
study. In the pioneering studies of Folkman et al., large T
antigen was expressed under the control of rat insulinCpromoter (Folkman et al., 1989). Large T antigen was suf-
ficient by itself to promote the full course of tumor progres-
sion from hyperplasia of pancreatic b-cells to carcinoma.
Emergence of carcinoma was preceded by angiogenesis
in a small fraction of hyperplastic islands that correlated
with carcinoma incidence. This phenomenon was called
the angiogenic switch. In subsequent studies Perl et al.
used crosses between Rip1Tag2 and Rip1 dn E-cadherin
mice and suggested that dn E-cadherin can induce tumor
progression. Double transgenic mice showed doubling of
carcinoma incidence and low level of lymph node metas-
tasis (Perl et al., 1998). In their study, no data on angiogen-
esis were reported. Moreover, causal evidence for the role
of dn E-cadherin at specific steps of tumor progression
was not provided and would have required use of revers-
ible expression systems. We have used such a conditional
expression system and demonstrated that formation of
blood and lymph vessels in tumors entirely depends onancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc. 155
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maintained for up to 2 months after induction and involved
apoptosis of endothelial cells upon restoration of E-cad-
herin expression. Appearance of blood and lymph vessels
in the tumors correlated with increased size of individual
tumor nodules some of which reached macroscopic
scale. As in the case of angiogenesis, the dn E-cadherin
induced increase in tumor volume required continuous
presence of DOX. Long-term treatment did uncover an-
other important aspect of tumor vasculogenesis relating
to reversibility. After 4 months induction, vessels self-sta-
bilized, presumably due to acquisition of a quiescent dif-
ferentiated phenotype and recruitment of pericytes (Risau,
1997; Nikolopoulos et al., 2004). As a consequence, DOX
withdrawal no longer leads endothelial cells to apoptosis.
Although these findings support the concept of tumor
therapy with angiogenesis inhibitors (Folkman, 2006),
they also point to a limitation. It may be that treatment of
patients with established tumors with a mature vascula-
ture will only induce stasis but not tumor regression.
E-Cadherin Disruption Promotes Progression
of Angiogenic Tumors to Invasive Growth
and Micrometastasis
Besides induction of angiogenesis, cdh1 deletion or dn
E-cadherin induction also cooperates with C-RAF BXB
in driving proliferation and invasive growth. The increase
in proliferation rates was in the order of 50% and led to ap-
pearance of macroscopic tumors on the surface of lungs
by the age of 8 months. Cooperation in growth stimulation
required continuous induction of dn E-cadherin as a 4
month ON DOX/4 month OFF DOX schedule reduced tu-
mor volume to the level C-RAF BXB. These data may sug-
gest a continuous need for neoangiogenesis or result from
cell-autonomous effects of E-cadherin loss on cell-cycle
control. In addition to cooperation in proliferation, loss of
E-cadherin function changed the growth pattern of tumor
cells in tumor foci. Tumors in compound mice were more
dispersed and expanded into the lung parenchyma with-
out signs of classical EMT. This finding is consistent with
a previous study where expression of dn E-cadherin in
Rip1Tag2 transgenic mice also led to invasive growth
and lymph node metastasis without complete EMT
conversion (Perl et al., 1998). Furthermore, our data on
E-cadherin gene ablation in SP-C C-RAF BXB mice are
in agreement with a large body of literature that links
loss of E-cadherin expression with adenoma-carcinoma
progression (Birchmeier, 2005; Berx and Van Roy, 2001;
Cavallaro and Christofori, 2004) and with a recent publica-
tion by Derksen et al. who did not observe classical EMT in
invasive lobular breast cancer upon cdh1 loss (Derksen
et al., 2006). Our data on EMT agree well with those of
Perl and Derksen (Perl et al., 1998; Derksen et al., 2006).
While we cannot exclude that dispersed cells in tumor
foci of induced compound mice have a transient EMT in
their history, we have no evidence for such an event as
we did not find cells double-positive for vimentin/proSPC
or N-cadherin/proSPC expression. On the other hand, as156 Cancer Cell 12, 145–159, August 2007 ª2007 Elsevier Inc.cells with disrupted E-cadherin appear spindle-shaped,
this may be considered as a partial EMT.
Angiogenic switch followed by progression of induced
tumors to invasive adenocarcinomas was not in itself suf-
ficient to promote metastatic spread. This required addi-
tional time (at least 5 months) and led to micrometastasis
into regional lymph nodes and occasionally into bone
marrow. Micrometastasis was completely dependent on
continuous DOX treatment. One explanation for the time
requirement might be increase in tumor mass that would
raise the probability for an infrequent event such as gener-
ation of metastatic cells to take place. The fact that micro-
metastasis occurred late whereas angiogenesis and cell
dispersion were early events is consistent with the con-
cept that additional genetic changes are required in the
tumor cells before they express (mutated) metastasis
gene(s) (Hanahan and Weinberg, 2000). Tumor cells
equipped with a ‘‘metastatic signature’’ should be able
to grow into new tumors at distant sites. That is not the
case in micrometastasis (Schardt et al., 2005) that may
spread dormant tumor cells. Dormant tumor cells are initi-
ated cells using the language of two-stage carcinogenesis
(Rous and Kidd, 1941; Berenblum, 1954). These cryptic
transformants require a tumor-promoting condition which
may utilize regenerative signaling pathways (Maurange
et al., 2006). The dependence of micrometastasis on con-
tinued dn E-cadherin expression suggests that the ability
of tumor cells to induce angiogenesis may be required for
seeding at distant sites but may not be sufficient for clonal
expansion at that site. The combined data suggest that
the step in tumor progression that is being induced by dis-
ruption of E-cadherin may be limited to acquisition of
a self-seeding phenotype that includes micrometastasis
(Norton and Massaque´, 2006). It will be interesting to de-
termine whether strengthening the growth engine by com-
bination of RAF with other oncogenes would overcome
this limitation. We are currently exploring this possibility
in transplantation experiments with fractionated tumor
cells.
Disruption of E-Cadherin Activates
b-Catenin Signaling
Quantitative RT-PCR of acutely induced compound mice
identified 3 classes of angiogenic factors that showed
a 2-fold increase. These were VEGF-A, VEGF-C and its re-
ceptor Flt-4, as well as Tie1, endothelial cell adhesion mol-
ecule VE-cadherin and b-catenin together with cyclin D1.
VEGF-A and VEGF-C were also induced in vitro in tran-
sient transfection experiments with a dn E-cadherin ex-
pression vector in mouse and human cell lines derived
from NSCLC. The simplest explanation for the combined
in vivo and in vitro findings is a signaling cascade connect-
ing dn E-cadherin or cdh1 inactivation via b-catenin with
angiogenesis target genes. Such a chain is supported by
in vitro siRNA experiments against b-catenin and identifies
E-cadherin disruption for the first time as a signaling
condition. Induction of VEGF-A, not VEGF-C was b-cate-
nin-dependent, consistent with an earlier report which
described VEGF-A as a direct b-catenin target gene in
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human endothelial cells (HUVECs), b-catenin was de-
scribed to mediate both VEGF-A and VEGF-C expression
(Skurk et al., 2005) which parallels the pattern we found in
our lungs from DOX-induced triple transgenic mice.
VEGF-A and VEGF-C have prognostic value for NSCLC
(Nakashima et al., 2004), and the VEGF-C/Flt-4 axis has
been shown to promote invasion and metastasis of lung
A549 and other cancer cell lines (Su et al., 2006). On the
basis of our and these literature data we conclude that
the mechanism of angiogenic switch induction and
subsequent tumor progression induced by disruption of
E-cadherin involves signaling via b-catenin and VEGF-A/
VEGF-C.
Upregulation of b-Catenin Targets by Chronic
Disruption of E-Cadherin in Alveolar Epithelial Cells
Includes Genes from Endodermal Lineages
Further evidence that b-catenin functions as a critical ef-
fector of chronic E-cadherin disruption was obtained by
RT-PCR experiments using RNA from purified type II cells
of lung tumors. These experiments revealed upregulation
of a set of genes that was previously reported to be in-
duced in embryonic lungs with a SP-C promoter-driven
constitutively active b-catenin transgene (Okubo and Ho-
gan, 2004). Selected candidate genes included endoder-
mal and other lineage markers and Wnt pathway and
cell-cycle regulators. Our data suggest reprogramming
of C-RAF-transformed type II cells and raise the possibility
that constitutive signaling by the Wnt pathway simulta-
neously with mitogenic cascade signaling may erode
phenotypic stability. There is evidence that these two
pathways normally function in an alternating fashion and
thus constitute the core element of a developmental oscil-
lator (Deque´ant et al., 2006). As combined signaling is
a prerequisite for micrometastasis in our model, it is
tempting to speculate that ontogenetically younger pro-




Generation of transgenic mice conditionally expressing dn E-cadherin
is described in detail in Supplemental Experimental Procedures. All an-
imal studies were approved by the Bavarian State authorities for ani-
mal experimentation.
RNA Isolation and RT-PCR Analysis
Protocols for RNA isolation from microdissected mouse lung tumors,
3041, A549 lung tumor cells and total mouse lungs, RT-PCR and
real-time RT-PCR procedures are given in Supplemental Experimental
Procedures.
Cell Culture and Transfections
Mouse 3041 alveologenic lung adenocarcinoma (Rizzino et al., 1982)
and human lung carcinoma A549 epithelial cells (ATCC CCL-185)
were maintained in DMEM supplemented with 10% calf serum. Cells
were seeded into 12-well plates 24 hr before transfection. For DNA
transfection, Lipofectamine 2000 reagent (Invitrogen) was used. siRNA
against mouse b-catenin (sc-29210, Santa Cruz) and human b-catenin(CTNNB1, M-003482, Upstate) were transfected using transfection
reagent (sc-29528, Santa Cruz) according to the manufacturer’s
descriptions. Validated nonsilencing control siRNA (Alexa Fluor 488
Labeled, QIAGEN) was always included for control cells (mock) and
for siRNA transfection efficiency. Transfected cells were starved for
5 hr in the absence of serum and antibiotics followed by recovery in
complete medium for 20 hr. Cells were subsequently transfected
with plasmids Tet-O dn E-cadherin, SP-C rtTA, SP-C C-RAF BXB
alone or combination, and b-catenin 4S plasmid (Herzig et al., 2007)
using lipofectamine reagent. Cells were harvested 24 hr later and
RNA extracted using TRIzol reagent (Invitrogen). Knockdown
efficiency of b-catenin was determined by b-catenin immunostaining
and by qRT-PCR. Transfection efficiency of DNA constructs was mon-
itored by qRT-PCR, staining, and luciferase assay (Promega).
Luciferase Activity Assays
Mice were sacrificed by lethal injection of ketanest (Parke-Davis) to-
gether with rompun (Bayer). After lung dissection, the tissue was ho-
mogenized in lysis buffer containing 0.25 M Tris, pH 7.6, 1% Triton
X-100. After centrifugation at 11,000 rpm for 10 min, the luciferase ac-
tivity in the supernatant was measured in a luciferase assay according
to the manufacturer’s instructions (Promega). Protein concentrations
were determined with the Bradford protein assay. Luciferase activity
was normalized to protein concentration to calculate relative light units
(RLU) per mg protein.
Terminal Deoxynucleotidyltransferase-Mediated dUTP-Biotin
Nick End Labeling Assay
Frozen lung sections of triple transgenic mice were stained according
to the Dead End Fluorometric TUNEL System instructions (Promega).
Immunofluorescence Double Staining for CD31/PECAM-1 and TUNEL
was as described (Solorzano et al., 2001).
Immunoblotting and Immunoprecipitation
Procedures were as detailed in Supplemental Experimental Proce-
dures.
Immunofluorescence and Immunohistochemistry Microscopy
Animals were sacrificed and lungs were fixed under 25 cm water pres-
sure with 4% PBS buffered formalin. Histology was done on formalin-
fixed, paraffin-embedded lung specimen. 6 mm-cut sections were de-
paraffinized, rehydrated in graded alcohols and Hematoxylin and eosin
stained. Details of staining protocols are given in Supplemental Exper-
imental Procedures.
Histopathology
Preparation of embedded tissues and quantitative assays for lung tu-
mor development are described in Supplemental Experimental Proce-
dures.
The Graphpad Prism version 4.00 (Graphpad Software, Inc, San
Diego, CA) software programs were used for all statistical analysis
and graphing. For all tests, statistical significance was considered to
be at the p < 0.05 level.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, eight supplemental figures, and two supplemental tables and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/2/145/DC1/.
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